ArticleInfection and immunity2005
CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine.
Article in Infection and immunity, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 109 citations in OpenAlex.
- Article
- Adjuvants for COVID-19 Vaccines.Vaccines · 2023Review
- Enhancement of Immune Response of Bioconjugate Nanovaccine by Loading of CpG through Click Chemistry.Journal of personalized medicine · 2023Article
- Ex vivo dendritic cell-based (DC) vaccine pulsed with a low dose of liposomal antigen and CpG-ODN improved PD-1 blockade immunotherapy.Scientific reports · 2021Article
- TRAF6-IRF5 kinetics, TRIF, and biophysical factors drive synergistic innate responses to particle-mediated MPLA-CpG co-presentation.Science advances · 2021Article
- Photo-responsive degradable hollow mesoporous organosilica nanoplatforms for drug delivery.Journal of nanobiotechnology · 2020Article
- A CpG oligodeoxynucleotide enhances the immune response to rabies vaccination in mice.Virology journal · 2018Article
- TLR9 mediates S. aureus killing inside osteoblasts via induction of oxidative stress.BMC microbiology · 2016Article
- Use of nanoparticles to deliver immunomodulatory oligonucleotides.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2016Review
- Optimization, Production, and Characterization of a CpG-Oligonucleotide-Ficoll Conjugate Nanoparticle Adjuvant for Enhanced Immunogenicity of Anthrax Protective Antigen.Bioconjugate chemistry · 2016Article
- Peptide/protein vaccine delivery system based on PLGA particles.Human vaccines & immunotherapeutics · 2016Review
- A CpG-Ficoll Nanoparticle Adjuvant for Anthrax Protective Antigen Enhances Immunogenicity and Provides Single-Immunization Protection against Inhaled Anthrax in Monkeys.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants.The Journal of clinical investigation · 2015Article
- CpG Oligonucleotides as Cancer Vaccine Adjuvants.Vaccines · 2015Review
- Liposome-antigen-nucleic acid complexes protect mice from lethal challenge with western and eastern equine encephalitis viruses.Journal of virology · 2014Article
- Recent progress concerning CpG DNA and its use as a vaccine adjuvant.Expert review of vaccines · 2014Review
- The impact of "omic" and imaging technologies on assessing the host immune response to biodefence agents.Journal of immunology research · 2014Review
- Engineering nano- and microparticles to tune immunity.Advanced materials (Deerfield Beach, Fla.) · 2012Review
- High-mobility group nucleosome-binding protein 1 acts as an alarmin and is critical for lipopolysaccharide-induced immune responses.The Journal of experimental medicine · 2012Article
- Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system.International journal of nanomedicine · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To reduce the biothreat posed by anthrax, efforts are under way to improve the protection afforded by vaccination. This work examines the ability of immunostimulatory CpG oligodeoxynucleotides (ODN) adsorbed onto cationic polylactide-co-glycolide (PLG) microparticles (CpG ODN-PLG) to accelerate and boost the protective immunity elicited by Anthrax Vaccine Adsorbed (AVA, the licensed human anthrax vaccine). The results indicate that coadministering CpG ODN-PLG with AVA induces a stronger and faster immunoglobulin G response against the protective antigen of anthrax than AVA alone. Immunized mice were protected from lethal anthrax challenge within 1 week of vaccination with CpG ODN-PLG plus AVA, with the level of protection correlating with serum immunoglobulin G anti-protective antigen titers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.